Renbio INC. - AOI#25(fastx) r & d for MYO technology for DNA-based delivery of anti-influenza antibodies to large animals
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50124C00017
- Awardee
-
Renbio, Inc. UEI NMYHCDQN7DR3
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $749,289
Award facts
- Opportunity
-
- BAA22100SOL00003 Solicitation number
- Contract value 100% obligated
- $749,289.42 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- 1 offer Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- Astoria, NY 11101, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Original award | $749,289 |
About this award
Renbio, Inc. received a $749.3K firm fixed-price definitive contract from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, awarded on April 29, 2024, with completion scheduled for February 27, 2026. The contract, designated AOI#25 (FASTX), funds research and development for myo technology focused on DNA-based delivery of anti-influenza antibodies to large animals. The award was made without set-aside designation, indicating unrestricted competition. Work will be performed in Astoria, NY.
Renbio, a for-profit biotechnology firm registered as a federal contractor since 2016, specializes in innovative antibody delivery systems with applications in infectious disease prevention and treatment. The company's expertise in DNA-based antibody delivery aligns with HHS ASPR's mission to advance medical countermeasures and preparedness capabilities. Renbio's prior involvement in the "RRADD: Rapid Rational Antibody Design and Delivery" initiative through academic partnerships demonstrates its established capability in advancing rapid antibody development and delivery platforms for public health applications.
Quick answers
Who was awarded contract 75A50124C00017?
75A50124C00017 was awarded to Renbio, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on April 29, 2024.
How much is contract 75A50124C00017 worth?
The government has obligated $749,289 on 75A50124C00017.
Was contract 75A50124C00017 competed?
The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award